PARP2 is altered in 0.93% of malignant solid tumor patients [3].

PARP2 is an inclusion criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain PARP2 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [4].

PARP2 is altered in 5.26% of prostate adenocarcinoma patients [3].

PARP2 is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain PARP2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].

PARP2 is altered in 5.26% of prostate carcinoma patients [3].

PARP2 is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PARP2 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

PARP2 is altered in 3.03% of breast carcinoma patients [3].

PARP2 is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PARP2 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [4].

PARP2 is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PARP2 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [4].

PARP2 is altered in 1.92% of colorectal carcinoma patients [3].

PARP2 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PARP2 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

PARP2 is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PARP2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PARP2 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PARP2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP2 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

PARP2 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PARP2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PARP2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

PARP2 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PARP2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

PARP2 is altered in 1.82% of malignant intestinal neoplasm patients [3].

PARP2 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

PARP2 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].